4 unknown, 1 active not recruiting. 3 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Refractory or Relapsed Multiple Myeloma: new trials by email Literature Review of Refractory or Relapsed Multiple Myeloma trials Research Report on Refractory or Relapsed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) - Refractory or Relapsed Multiple Myeloma | Phase 3 | Active not recruiting | Celltrion | 473 | 2025-08-12 | 2026-10-27 |
| LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma LCAR-B4822M CAR-T Cell Immunotherapy - Refractory or Relapsed Multiple Myeloma | Phase 1 | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 10 | 2018-07-26 | 2018-12-14 |
| Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma CAR-BCMA T cells, Fludarabine, Cyclophosphamide - Refractory or Relapsed Multiple Myeloma | Phase 1 | Unknown | First Affiliated Hospital of Zhejiang University | 11 | 2018-03-23 | 2020-10-08 |
| Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma CAR-BCMA T cells, Fludarabine, Cyclophosphamide - Refractory or Relapsed Multiple Myeloma | Not applicable | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 6 | 2017-10-13 | 2020-10-12 |
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma LCAR-B38M CAR-T cell injection - Refractory or Relapsed Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Nanjing Legend Biotech Co. | 100 | 2015-10-02 | 2023-06-12 |
Multiple Myeloma (5)
Blood Protein Disorders (5) · Cardiovascular Diseases (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Hemorrhagic Disorders (5) · Hemostatic Disorders (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Plasma Cell (5) · Paraproteinemias (5) · Vascular Diseases (5)
Cyclophosphamide (2) · fludarabine (2)
Celltrion (1) · First Affiliated Hospital of Zhejiang University (1) · Nanjing Legend Biotech Co. (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
China (3) · Taiwan (1)
Haitao Meng, MD (1) · Jie Jin, MD (1) · Siguo Hao, MD (1) · Wan-Hong Zhao, MD, PhD (1)